APRIL (protein)
(Redirected fromTNFSF13)
| TNFSF13 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | TNFSF13,APRIL, CD256, TALL-2, TALL2, TRDL-1, ZTNF2, UNQ383/PRO715, TNLG7B, tumor necrosis factor superfamily member 13, TNF superfamily member 13 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM:604472;MGI:1916833;HomoloGene:56971;GeneCards:TNFSF13;OMA:TNFSF13 - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
A proliferation-inducing ligand(APRIL), also known astumor necrosis factor ligand superfamily member 13(TNFSF13), is aproteinof theTNFsuperfamily recognized by thecell surface receptorTACI.[5][6]It is encoded by theTNFSF13gene.[6]
Nomenclature
[edit]In thecluster of differentiationterminology, APRIL is designatedCD256.
Function
[edit]The protein encoded by this gene is a member of thetumor necrosis factorligand (TNF) ligand family. This protein is a ligand forTNFRSF17/BCMA, a member of theTNF receptorfamily. This protein and its receptor are both found to be important forB celldevelopment. In vivo experiments suggest an important role for APRIL in the long-term survival of plasma cells in the bone marrow. Mice deficient in APRIL have normal immune system development.[7]However, APRIL-deficient mice have also been reported to possess a reduced ability to support plasma cell survival.[8]In vitro experiments suggested that this protein may be able to induceapoptosisthrough its interaction with other TNF receptor family proteins such asTNFRSF6/FAS andTNFRSF14/HVEM.[9]Three alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
Interactions
[edit]TNFSF13 has been shown tointeractwithTNFRSF13B[10]andB-cell activating factor.[11]
Clinical significance
[edit]APRIL is being explored as a target for autoimmune diseases and B cell malignancies.[12]At least one anti-APRIL monoclonal antibody has been announced to enter phase I clinical trials formultiple myeloma.[13]
References
[edit]- ^abcGRCh38: Ensembl release 89: ENSG00000161955–Ensembl,May 2017
- ^abcGRCm38: Ensembl release 89: ENSMUSG00000089669–Ensembl,May 2017
- ^"Human PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^"Mouse PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer JL, et al. (September 1998)."APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth".The Journal of Experimental Medicine.188(6): 1185–1190.doi:10.1084/jem.188.6.1185.PMC2212534.PMID9743536.
- ^ab"Entrez Gene: TNFSF13 tumor necrosis factor (ligand) superfamily, member 13".National Library of Medicine. 10 October 2023.Retrieved13 October2023.
- ^Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, Lawrence D, et al. (February 2004)."APRIL-deficient mice have normal immune system development".Molecular and Cellular Biology.24(3): 997–1006.doi:10.1128/MCB.24.3.997-1006.2004.PMC321448.PMID14729948.
- ^Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, et al. (March 2008)."APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells".Blood.111(5): 2755–2764.doi:10.1182/blood-2007-09-110858.PMID18180376.
- ^Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahne M, Tschopp J, et al. (April 2001)."APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis".Cell Death and Differentiation.8(4): 403–410.doi:10.1038/sj.cdd.4400827.PMID11550092.
- ^Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, et al. (November 2000)."Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS".The Journal of Biological Chemistry.275(45): 35478–35485.doi:10.1074/jbc.M005224200.PMID10956646.
- ^Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, et al. (October 2002)."BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases".Journal of Immunology.169(8): 4314–4321.doi:10.4049/jimmunol.169.8.4314.PMID12370363.
- ^Ryan MC, Grewal IS (2009-01-01). "Targeting of BAFF and APRIL for Autoimmunity and Oncology". In Grewal IS (ed.).Therapeutic Targets of the TNF Superfamily.Advances in Experimental Medicine and Biology. Vol. 647. New York: Springer. pp. 52–63.doi:10.1007/978-0-387-89520-8_4.ISBN978-0-387-89519-2.PMID19760066.
- ^"Development of a first in class APRIL fully blocking antibody BION-1301 for the treatment of multiple myeloma".AACR 2017 Proceedings.April 2017.
Further reading
[edit]- Bossen C, Schneider P (October 2006). "BAFF, APRIL and their receptors: structure, function and signaling".Seminars in Immunology.18(5): 263–275.doi:10.1016/j.smim.2006.04.006.PMID16914324.
- Tangye SG, Bryant VL, Cuss AK, Good KL (October 2006). "BAFF, APRIL and human B cell disorders".Seminars in Immunology.18(5): 305–317.doi:10.1016/j.smim.2006.04.004.PMID16916610.
- Treml LS, Crowley JE, Cancro MP (October 2006). "BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells".Seminars in Immunology.18(5): 297–304.doi:10.1016/j.smim.2006.07.001.PMID16919470.
- Mackay F, Leung H (October 2006). "The role of the BAFF/APRIL system on T cell function".Seminars in Immunology.18(5): 284–289.doi:10.1016/j.smim.2006.04.005.PMID16931039.
- Maruyama K, Sugano S (January 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides".Gene.138(1–2): 171–174.doi:10.1016/0378-1119(94)90802-8.PMID8125298.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (October 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library".Gene.200(1–2): 149–156.doi:10.1016/S0378-1119(97)00411-3.PMID9373149.
- Shu HB, Hu WH, Johnson H (May 1999)."TALL-1 is a novel member of the TNF family that is down-regulated by mitogens".Journal of Leukocyte Biology.65(5): 680–683.doi:10.1002/jlb.65.5.680.PMID10331498.S2CID1498303.
- Cousin P, Billotte J, Chaubert P, Shaw P (January 2000). "Physical map of 17p13 and the genes adjacent to p53".Genomics.63(1): 60–68.doi:10.1006/geno.1999.6062.PMID10662545.
- Kelly K, Manos E, Jensen G, Nadauld L, Jones DA (February 2000). "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death".Cancer Research.60(4): 1021–1027.PMID10706119.
- Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, et al. (November 2000)."Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS".The Journal of Biological Chemistry.275(45): 35478–35485.doi:10.1074/jbc.M005224200.PMID10956646.
- Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, et al. (September 2000). "APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity".Nature Immunology.1(3): 252–256.doi:10.1038/79802.PMID10973284.S2CID6799584.
- López-Fraga M, Fernández R, Albar JP, Hahne M (October 2001)."Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase".EMBO Reports.2(10): 945–951.doi:10.1093/embo-reports/kve198.PMC1084076.PMID11571266.
- Stein JV, López-Fraga M, Elustondo FA, Carvalho-Pinto CE, Rodríguez D, Gómez-Caro R, et al. (June 2002)."APRIL modulates B and T cell immunity".The Journal of Clinical Investigation.109(12): 1587–1598.doi:10.1172/JCI15034.PMC151011.PMID12070306.
- Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. (September 2002)."DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL".Nature Immunology.3(9): 822–829.doi:10.1038/ni829.PMC4621779.PMID12154359.
- Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, et al. (October 2002)."BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases".Journal of Immunology.169(8): 4314–4321.doi:10.4049/jimmunol.169.8.4314.PMID12370363.
- Pradet-Balade B, Medema JP, López-Fraga M, Lozano JC, Kolfschoten GM, Picard A, et al. (November 2002)."An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein".The EMBO Journal.21(21): 5711–5720.doi:10.1093/emboj/cdf565.PMC131062.PMID12411489.
External links
[edit]- TNFSF13+protein,+humanat the U.S. National Library of MedicineMedical Subject Headings(MeSH)
- HumanTNFSF13genome location andTNFSF13gene details page in theUCSC Genome Browser.
This article incorporates text from theUnited States National Library of Medicine,which is in thepublic domain.